Analyzing Adverum Biotechnologies (NASDAQ:ADVM) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF)

Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) and Adverum Biotechnologies (NASDAQ:ADVM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.

Profitability

This table compares Quantum Genomics Société Anonyme and Adverum Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quantum Genomics Société Anonyme	N/A	N/A	N/A
Adverum Biotechnologies	N/A	-65.14%	-40.52%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Quantum Genomics Société Anonyme and Adverum Biotechnologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Genomics Société Anonyme	0	0	0	0	0.00
Adverum Biotechnologies	0	1	5	0	2.83

Adverum Biotechnologies has a consensus price target of $27.83, indicating a potential upside of 554.90%. Given Adverum Biotechnologies’ stronger consensus rating and higher probable upside, analysts clearly believe Adverum Biotechnologies is more favorable than Quantum Genomics Société Anonyme.

Institutional & Insider Ownership

48.2% of Adverum Biotechnologies shares are held by institutional investors. 4.2% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Quantum Genomics Société Anonyme and Adverum Biotechnologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Genomics Société Anonyme	N/A	N/A	N/A	N/A	N/A
Adverum Biotechnologies	$1.00 million	88.41	-$117.17 million	($5.99)	-0.71

Quantum Genomics Société Anonyme has higher earnings, but lower revenue than Adverum Biotechnologies.

Risk and Volatility

Quantum Genomics Société Anonyme has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Summary

Adverum Biotechnologies beats Quantum Genomics Société Anonyme on 7 of the 9 factors compared between the two stocks.

About Quantum Genomics Société Anonyme

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.